Source 1primary paper2025MED
Toolkit/dual-effector CAR-NK + CAR-MΦ regimen
dual-effector CAR-NK + CAR-MΦ regimen
Also known as: CAR-NK+ CAR-MΦ
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
dual-effector regimens (CAR-NK+ CAR-MΦ)
Usefulness & Problems
Why this is useful
This regimen combines CAR-NK and CAR-MΦ as a dual-effector strategy. The abstract presents it as an emerging approach for solid tumors.; combinatorial engineered cell therapy in solid tumors
Source:
This regimen combines CAR-NK and CAR-MΦ as a dual-effector strategy. The abstract presents it as an emerging approach for solid tumors.
Source:
combinatorial engineered cell therapy in solid tumors
Problem solved
The abstract suggests it may help overcome barriers and improve durable, tumor-selective responses.; may help overcome barriers to durable, tumor-selective responses
Source:
The abstract suggests it may help overcome barriers and improve durable, tumor-selective responses.
Source:
may help overcome barriers to durable, tumor-selective responses
Problem links
may help overcome barriers to durable, tumor-selective responses
LiteratureThe abstract suggests it may help overcome barriers and improve durable, tumor-selective responses.
Source:
The abstract suggests it may help overcome barriers and improve durable, tumor-selective responses.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
cross-talk with adaptive immunitycytokine secretionmhc-unrestricted cytotoxicityphagocytosistrogocytosisTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
The approach requires both engineered NK-cell and engineered macrophage products.; requires coordinated use of both CAR-NK and CAR-macrophage products
However, persistent challenges remain, including transient in vivo survival, manufacturing complexity, and risks of off-target inflammation.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Early-phase clinical studies such as CT-0508 demonstrate feasibility and tumor-microenvironment remodeling with CAR-MΦ.
Early-phase clinical studies (e.g., CT-0508) demonstrate feasibility and TME remodeling with CAR-MΦ.
CAR-NK and CAR-MΦ have emerged as promising innate immune alternatives to conventional CAR-T cells for solid tumors.
innate immune cell platforms, particularly chimeric antigen receptor-engineered natural killer (CAR-NK) cells and chimeric antigen receptor-macrophages (CAR-MΦ), have emerged as promising alternatives
Recent CAR-NK and CAR-MΦ advances include lineage-specific intracellular signaling domains, novel effector constructs, and scalable iPSC-derived platforms.
We highlight key innovations, including the use of lineage-specific intracellular signaling domains (e.g., DAP12, 2B4, FcRγ), novel effector constructs (e.g., NKG7-overexpressing CARs, TME-responsive CARs), and scalable induced pluripotent stem cell (iPSC)-derived platforms.
Dual-effector regimens, cytokine-modulated cross-support, and bispecific or logic-gated CARs may overcome current barriers and provide more durable, tumor-selective responses.
Emerging combinatorial strategies, such as dual-effector regimens (CAR-NK+ CAR-MΦ), cytokine-modulated cross-support, and bispecific or logic-gated CARs, may overcome these barriers and provide more durable, tumor-selective responses.
Persistent challenges for CAR-NK and CAR-MΦ include transient in vivo survival, manufacturing complexity, and risks of off-target inflammation.
However, persistent challenges remain, including transient in vivo survival, manufacturing complexity, and risks of off-target inflammation.
Preclinical data support enhanced antitumor activity of CAR-NK and CAR-MΦ through MHC-unrestricted cytotoxicity, phagocytosis, trogocytosis, cytokine secretion, and cross-talk with adaptive immunity.
Preclinical data support enhanced antitumor activity through mechanisms such as major histocompatibility complex (MHC)-unrestricted cytotoxicity, phagocytosis, trogocytosis, cytokine secretion, and cross-talk with adaptive immunity.
Approval Evidence
1 source1 linked approval claimfirst-pass slug dual-effector-car-nk-car-m-regimen
dual-effector regimens (CAR-NK+ CAR-MΦ)
Source:
forward looking strategysupports
Dual-effector regimens, cytokine-modulated cross-support, and bispecific or logic-gated CARs may overcome current barriers and provide more durable, tumor-selective responses.
Emerging combinatorial strategies, such as dual-effector regimens (CAR-NK+ CAR-MΦ), cytokine-modulated cross-support, and bispecific or logic-gated CARs, may overcome these barriers and provide more durable, tumor-selective responses.
Source:
Comparisons
Source-stated alternatives
The abstract mentions cytokine-modulated cross-support and bispecific or logic-gated CARs as other emerging strategies.
Source:
The abstract mentions cytokine-modulated cross-support and bispecific or logic-gated CARs as other emerging strategies.
Source-backed strengths
combines two innate immune engineered cell platforms
Source:
combines two innate immune engineered cell platforms
Compared with coherent anti-Stokes Raman scattering
The abstract mentions cytokine-modulated cross-support and bispecific or logic-gated CARs as other emerging strategies.
Shared frame: source-stated alternative in extracted literature
Strengths here: combines two innate immune engineered cell platforms.
Source:
The abstract mentions cytokine-modulated cross-support and bispecific or logic-gated CARs as other emerging strategies.
Compared with logic-gated CAR designs
The abstract mentions cytokine-modulated cross-support and bispecific or logic-gated CARs as other emerging strategies.
Shared frame: source-stated alternative in extracted literature
Strengths here: combines two innate immune engineered cell platforms.
Source:
The abstract mentions cytokine-modulated cross-support and bispecific or logic-gated CARs as other emerging strategies.
Compared with logic-gated CAR forms
The abstract mentions cytokine-modulated cross-support and bispecific or logic-gated CARs as other emerging strategies.
Shared frame: source-stated alternative in extracted literature
Strengths here: combines two innate immune engineered cell platforms.
Source:
The abstract mentions cytokine-modulated cross-support and bispecific or logic-gated CARs as other emerging strategies.
Ranked Citations
- 1.